Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) bevacizurnab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC)

被引：0
|
作者：
Wardley, A.
Lohrisch, C.
Joy, A. A.
Young, S.
Yi, F. F.
Marme, A.
Dreosti, L.
Albanell, J.
Munoz, M.
Miles, D. W.
机构：
[1] Christie Hosp, Manchester, Lancs, England
[2] BC Canc Agcy, Vancouver, BC, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Hop Reg Sudbury Reg Hosp, Sudbury, ON, Canada
[5] Peking Union Med Coll, Beijing 100021, Peoples R China
[6] Chinese Acad Med Sci, Beijing 100037, Peoples R China
[7] Univ Tubingen, Tubingen, Germany
[8] Univ Pretoria, ZA-0002 Pretoria, South Africa
[9] Hosp del Mar, Barcelona, Spain
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Mt Vernon Canc Ctr, Middlesex, England
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116S / 116S
页数：1
相关论文
共 50 条
  • [31] First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in >2000 Patients (Pts).
    Thomssen, C.
    Pierga, J-Y
    Pritchard, K., I
    Biganzoli, L.
    Cortes-Funes, H.
    Petrakova, K.
    Kaufman, B.
    Smith, I. E.
    CANCER RESEARCH, 2009, 69 (24) : 854S - 854S
  • [32] SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)
    Lang, I.
    Inbar, M.
    Greil, R.
    Kahan, Z.
    Beslija, S.
    Steger, G. G.
    Stemmer, S. M.
    Zvribule, Z.
    Kaufman, B.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
  • [33] Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos Henrique
    Holgado, Esther
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhao, Jing
    Aktan, Gursel
    Karantza, Vassiliki
    Schmidi, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator's chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
    Miles, D. W.
    Ciruelos, E. M.
    Schneeweiss, A.
    Puglisi, F.
    Peretz-Yablonski, T.
    Campone, M.
    Bondarenko, I.
    Nowecki, Z.
    Errihani, H.
    Paluch-Shimon, S.
    Wardley, A. M.
    Merot, J. L.
    du Toit, Y.
    Klingbiel, D.
    Revelant, V.
    Bachelot, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S356 - S357
  • [35] Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49
    Schmid, Peter
    Sohn, Joo Hyuk
    Jerez Gilarranz, Yolanda
    Gonzalez-Cortijo, Lucia
    Sonnenblick, Amir
    Sabanathan, Dhanusha
    Korbenfeld, Ernesto
    Egle, Daniel
    Poirier, Brigitte
    Zagouri, Flora
    Matikas, Alexios
    Aksoy, Sercan
    Demirci, Umut
    Ramos-Elias, Pier
    Im, Seock-Ah
    Cardoso, Fatima
    Jia, Liyi
    Hirshfield, Kim
    Tryfonidis, Konstantinos
    Rugo, Hope S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 233 - 234
  • [36] The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)
    Tutt, Andrew
    Ellis, Paul
    Kilburn, Lucy
    Gilett, Cheryl
    Pinder, Sarah
    Abraham, Jacinta
    Barrett, Sophie
    Barrett-Lee, Peter
    Chan, Stephen
    Cheang, Maggie
    Dowsett, Mitch
    Fox, Lisa
    Gazinska, Patrycja
    Grigoriadis, Anita
    Gutin, Alexander
    Harper-Wynne, Catherine
    Hatton, Matthew
    Kernaghan, Sarah
    Lanchbury, Jerry
    Morden, James
    Owen, Julie
    Parikh, Jyoti
    Parker, Peter
    Rahman, Nazneen
    Roylance, Rebecca
    Shaw, Adam
    Smith, Ian
    Thompson, Rose
    Timms, Kirsten
    Tovey, Holly
    Wardley, Andrew
    Wilson, Gregory
    Harries, Mark
    Bliss, Judith
    CANCER RESEARCH, 2015, 75
  • [37] Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC)
    Smith, I. E.
    Biganzoli, L.
    Cortes-Funes, H.
    Stroyakovskiy, D.
    Franke, F. A.
    Chlistalla, A.
    Pierga, J-Y
    Thomssen, C.
    Pritchard, K.
    CANCER RESEARCH, 2009, 69 (02) : 286S - 286S
  • [38] A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival
    Awada, A.
    Kaufman, P. A.
    Yelle, L.
    Cortes, J.
    Wanders, J.
    O'Shaughnessy, J.
    Olivo, M. S.
    He, Y.
    Garzon, F.
    Dutcus, C. E.
    Binder, T. A.
    Twelves, C.
    Perez, E. A.
    CANCER RESEARCH, 2013, 73
  • [39] Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
    Binghe Xu
    Wei Li
    Qingyuan Zhang
    Zhimin Shao
    Qiao Li
    Xiaojia Wang
    Huiping Li
    Tao Sun
    Yongmei Yin
    Hong Zheng
    Jifeng Feng
    Hong Zhang
    Guiyuan Lei
    Eleonora Restuccia
    Breast Cancer Research and Treatment, 2020, 182 : 689 - 697
  • [40] Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
    Xu, Binghe
    Li, Wei
    Zhang, Qingyuan
    Shao, Zhimin
    Li, Qiao
    Wang, Xiaojia
    Li, Huiping
    Sun, Tao
    Yin, Yongmei
    Zheng, Hong
    Feng, Jifeng
    Zhang, Hong
    Lei, Guiyuan
    Restuccia, Eleonora
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (03) : 689 - 697
12345